[Androgen deprivation therapy in prostate cancer. Indication and systemic consequences]
- PMID: 22476802
- DOI: 10.1007/s00120-012-2808-7
[Androgen deprivation therapy in prostate cancer. Indication and systemic consequences]
Abstract
Androgen deprivation therapy (ADT) is effective in prolonging the progression free survival of patients with symptomatic/metastatic prostate cancer (PC). The reduction of clinical symptoms of tumour disease and the reduction of tumour growth and metastatic dissemination is accompanied by systemic consequences of testosterone deficiency. These are hot flushes, fatigue due to reduction of muscular strength and muscle mass as well as anaemia. Moreover, patients develop cognitive impairment und depressive mood. Weight gain with insulin resistance, disturbances of lipid metabolism and gynecomastia are other effects of androgen deficiency. A decrease in bone mineral density may lead to an increased susceptibility to bone fractures. There are several options to reduce these side effects of ADT, e.g. physical activity, dietary supplementation, tailored pharmacological therapy and psychotherapy. The knowledge of these adjuvant treatment options, despite their palliative character, is relevant to optimize the quality of life of these patients.
Similar articles
-
Androgen deprivation therapy: evidence-based management of side effects.BJU Int. 2013 Apr;111(4):543-8. doi: 10.1111/j.1464-410X.2012.11774.x. Epub 2013 Jan 25. BJU Int. 2013. PMID: 23351025 Review.
-
Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.Eur Urol Focus. 2020 Nov 15;6(6):1170-1179. doi: 10.1016/j.euf.2020.05.014. Epub 2020 Jul 18. Eur Urol Focus. 2020. PMID: 32690473 Review.
-
Complications of androgen deprivation therapy in prostate cancer.Curr Opin Urol. 2009 May;19(3):322-6. doi: 10.1097/MOU.0b013e32832a082c. Curr Opin Urol. 2009. PMID: 19318949 Review.
-
Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?Clin Endocrinol (Oxf). 2011 Mar;74(3):289-93. doi: 10.1111/j.1365-2265.2010.03939.x. Clin Endocrinol (Oxf). 2011. PMID: 21092052
-
Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.Med J Aust. 2011 Mar 21;194(6):301-6. doi: 10.5694/j.1326-5377.2011.tb02979.x. Med J Aust. 2011. PMID: 21426285 Review.
Cited by
-
[Antihormonal therapy in prostate cancer : Side effects].Urologe A. 2017 Apr;56(4):465-471. doi: 10.1007/s00120-017-0340-5. Urologe A. 2017. PMID: 28246761 German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical